Development costs for new therapeutics are rising on a continuous basis due to increasingly complex internal and external factors. I believe that it is of critical importance to invest an adequate effort in the starting phase of each pharmaceutical development. Making the best decision from a comprehensive pool of possible decisions defines the grade of innovation and thus the efficacy of the subsequent steps along the R&D pipeline.

"True innovation does not need primary optimization"


Dr. Stefan Langhammer

email: langhammer@ls-consultant.net

Professional experience: Companies and institutions

Max-Planck Institute for Molecular Genetics

The Scripps Research Institute

Robert Koch Institute

Accenture GmbH

Bayer-Schering Pharma AG

Novartis GmbH

Novartis AG

Pfizer GmbH

AstraZeneca GmbH

AbbVie GmbH

Peer-reviewer activities

Cellular Physiology and Biochemistry 

Tumor Biology

OncoTargets and Therapy

Oncology Reports

Oncology Letters

International Journal of Oncology

Drug Design, Development and Therapy

International Journal of  Nanomedicine